Literature DB >> 27571973

THPP target assignment reveals EchA6 as an essential fatty acid shuttle in mycobacteria.

Jonathan A G Cox1, Katherine A Abrahams1, Carlos Alemparte2, Sonja Ghidelli-Disse3, Joaquín Rullas2, Iñigo Angulo-Barturen2, Albel Singh1, Sudagar S Gurcha1, Vijayashankar Nataraj1, Stephen Bethell1, Modesto J Remuiñán2, Lourdes Encinas2, Peter J Jervis1, Nicholas C Cammack2, Apoorva Bhatt1, Ulrich Kruse3, Marcus Bantscheff3, Klaus Fütterer1, David Barros2, Lluis Ballell2, Gerard Drewes3, Gurdyal S Besra1.   

Abstract

Phenotypic screens for bactericidal compounds against drug-resistant tuberculosis are beginning to yield novel inhibitors. However, reliable target identification remains challenging. Here, we show that tetrahydropyrazo[1,5-a]pyrimidine-3-carboxamide (THPP) selectively pulls down EchA6 in a stereospecific manner, instead of the previously assigned target Mycobacterium tuberculosis MmpL3. While homologous to mammalian enoyl-coenzyme A (CoA) hydratases, EchA6 is non-catalytic yet essential and binds long-chain acyl-CoAs. THPP inhibitors compete with CoA-binding, suppress mycolic acid synthesis, and are bactericidal in a mouse model of chronic tuberculosis infection. A point mutation, W133A, abrogated THPP-binding and increased both the in vitro minimum inhibitory concentration and the in vivo effective dose 99 in mice. Surprisingly, EchA6 interacts with selected enzymes of fatty acid synthase II (FAS-II) in bacterial two-hybrid assays, suggesting essentiality may be linked to feeding long-chain fatty acids to FAS-II. Finally, our data show that spontaneous resistance-conferring mutations can potentially obscure the actual target or alternative targets of small molecule inhibitors.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27571973     DOI: 10.1038/nmicrobiol.2015.6

Source DB:  PubMed          Journal:  Nat Microbiol        ISSN: 2058-5276            Impact factor:   17.745


  41 in total

1.  Delayed fragmentation and optimized isolation width settings for improvement of protein identification and accuracy of isobaric mass tag quantification on Orbitrap-type mass spectrometers.

Authors:  Mikhail M Savitski; Gavain Sweetman; Manor Askenazi; Jarrod A Marto; Manja Lang; Nico Zinn; Marcus Bantscheff
Journal:  Anal Chem       Date:  2011-11-04       Impact factor: 6.986

2.  Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis.

Authors:  Wei Li; Ashutosh Upadhyay; Fabio L Fontes; E Jeffrey North; Yuehong Wang; Debbie C Crans; Anna E Grzegorzewicz; Victoria Jones; Scott G Franzblau; Richard E Lee; Dean C Crick; Mary Jackson
Journal:  Antimicrob Agents Chemother       Date:  2014-08-18       Impact factor: 5.191

3.  Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes.

Authors:  Marcus Bantscheff; Carsten Hopf; Mikhail M Savitski; Antje Dittmann; Paola Grandi; Anne-Marie Michon; Judith Schlegl; Yann Abraham; Isabelle Becher; Giovanna Bergamini; Markus Boesche; Manja Delling; Birgit Dümpelfeld; Dirk Eberhard; Carola Huthmacher; Toby Mathieson; Daniel Poeckel; Valérie Reader; Katja Strunk; Gavain Sweetman; Ulrich Kruse; Gitte Neubauer; Nigel G Ramsden; Gerard Drewes
Journal:  Nat Biotechnol       Date:  2011-01-23       Impact factor: 54.908

4.  SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis.

Authors:  Kapil Tahlan; Regina Wilson; David B Kastrinsky; Kriti Arora; Vinod Nair; Elizabeth Fischer; S Whitney Barnes; John R Walker; David Alland; Clifton E Barry; Helena I Boshoff
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

5.  Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis.

Authors:  Joaquín Rullas; Juan Ignacio García; Manuela Beltrán; Pere-Joan Cardona; Neus Cáceres; José Francisco García-Bustos; Iñigo Angulo-Barturen
Journal:  Antimicrob Agents Chemother       Date:  2010-02-16       Impact factor: 5.191

6.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

Review 7.  Mechanisms and structures of crotonase superfamily enzymes--how nature controls enolate and oxyanion reactivity.

Authors:  R B Hamed; E T Batchelar; I J Clifton; C J Schofield
Journal:  Cell Mol Life Sci       Date:  2008-08       Impact factor: 9.261

8.  Identification of the dehydratase component of the mycobacterial mycolic acid-synthesizing fatty acid synthase-II complex.

Authors:  Alistair K Brown; Apoorva Bhatt; Albel Singh; Elesh Saparia; Alex F Evans; Gurdyal S Besra
Journal:  Microbiology       Date:  2007-12       Impact factor: 2.777

9.  Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane.

Authors:  Anna E Grzegorzewicz; Ha Pham; Vijay A K B Gundi; Michael S Scherman; Elton J North; Tamara Hess; Victoria Jones; Veronica Gruppo; Sarah E M Born; Jana Korduláková; Sivagami Sundaram Chavadi; Christophe Morisseau; Anne J Lenaerts; Richard E Lee; Michael R McNeil; Mary Jackson
Journal:  Nat Chem Biol       Date:  2012-02-19       Impact factor: 15.040

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  32 in total

1.  A piperidinol-containing molecule is active against Mycobacterium tuberculosis by inhibiting the mycolic acid flippase activity of MmpL3.

Authors:  Christian Dupont; Yushu Chen; Zhujun Xu; Françoise Roquet-Banères; Mickaël Blaise; Anne-Kathrin Witt; Faustine Dubar; Christophe Biot; Yann Guérardel; Florian P Maurer; Shu-Sin Chng; Laurent Kremer
Journal:  J Biol Chem       Date:  2019-09-27       Impact factor: 5.157

2.  Open Lab as a source of hits and leads against tuberculosis, malaria and kinetoplastid diseases.

Authors:  Lluís Ballell; Mike Strange; Nicholas Cammack; Alan H Fairlamb; Leszek Borysiewicz
Journal:  Nat Rev Drug Discov       Date:  2016-03-29       Impact factor: 84.694

3.  High-throughput metabolomic analysis predicts mode of action of uncharacterized antimicrobial compounds.

Authors:  Mattia Zampieri; Balazs Szappanos; Maria Virginia Buchieri; Andrej Trauner; Ilaria Piazza; Paola Picotti; Sébastien Gagneux; Sonia Borrell; Brigitte Gicquel; Joel Lelievre; Balazs Papp; Uwe Sauer
Journal:  Sci Transl Med       Date:  2018-02-21       Impact factor: 17.956

4.  MmpL3 is the flippase for mycolic acids in mycobacteria.

Authors:  Zhujun Xu; Vladimir A Meshcheryakov; Giovanna Poce; Shu-Sin Chng
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-11       Impact factor: 11.205

5.  Identification of New MmpL3 Inhibitors by Untargeted and Targeted Mutant Screens Defines MmpL3 Domains with Differential Resistance.

Authors:  John T Williams; Elizabeth R Haiderer; Garry B Coulson; Kayla N Conner; Edmund Ellsworth; Chao Chen; Nadine Alvarez-Cabrera; Wei Li; Mary Jackson; Thomas Dick; Robert B Abramovitch
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

6.  HC2091 Kills Mycobacterium tuberculosis by Targeting the MmpL3 Mycolic Acid Transporter.

Authors:  Huiqing Zheng; John T Williams; Garry B Coulson; Elizabeth R Haiderer; Robert B Abramovitch
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

7.  Functional reconstitution of the Mycobacterium tuberculosis long-chain acyl-CoA carboxylase from multiple acyl-CoA subunits.

Authors:  Bernardo Bazet Lyonnet; Lautaro Diacovich; Gabriela Gago; Lucie Spina; Fabienne Bardou; Anne Lemassu; Annaïk Quémard; Hugo Gramajo
Journal:  FEBS J       Date:  2017-03-19       Impact factor: 5.542

Review 8.  The emerging role of mass spectrometry-based proteomics in drug discovery.

Authors:  Felix Meissner; Jennifer Geddes-McAlister; Matthias Mann; Marcus Bantscheff
Journal:  Nat Rev Drug Discov       Date:  2022-03-29       Impact factor: 112.288

9.  Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against Mycobacterium tuberculosis.

Authors:  Yumi Park; Angela Pacitto; Tracy Bayliss; Laura A T Cleghorn; Zhe Wang; Travis Hartman; Kriti Arora; Thomas R Ioerger; Jim Sacchettini; Menico Rizzi; Stefano Donini; Tom L Blundell; David B Ascher; Kyu Rhee; Ardala Breda; Nian Zhou; Veronique Dartois; Surendranadha Reddy Jonnala; Laura E Via; Valerie Mizrahi; Ola Epemolu; Laste Stojanovski; Fred Simeons; Maria Osuna-Cabello; Lucy Ellis; Claire J MacKenzie; Alasdair R C Smith; Susan H Davis; Dinakaran Murugesan; Kirsteen I Buchanan; Penelope A Turner; Margaret Huggett; Fabio Zuccotto; Maria Jose Rebollo-Lopez; Maria Jose Lafuente-Monasterio; Olalla Sanz; Gracia Santos Diaz; Joël Lelièvre; Lluis Ballell; Carolyn Selenski; Matthew Axtman; Sonja Ghidelli-Disse; Hannah Pflaumer; Markus Bösche; Gerard Drewes; Gail M Freiberg; Matthew D Kurnick; Myron Srikumaran; Dale J Kempf; Simon R Green; Peter C Ray; Kevin Read; Paul Wyatt; Clifton E Barry; Helena I Boshoff
Journal:  ACS Infect Dis       Date:  2016-10-17       Impact factor: 5.084

10.  Identification and validation of the mode of action of the chalcone anti-mycobacterial compounds.

Authors:  B Anagani; J Singh; J P Bassin; G S Besra; C Benham; T R K Reddy; J A G Cox; M Goyal
Journal:  Cell Surf       Date:  2020-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.